Progestins abrogate estrogen-induced changes in the insulin-like growth factor axis

American Journal of Obstetrics and Gynecology

Volumn 183, Issue 3, 2000, Pages 593-600

  Heald, Adrian ^a   Selby, Peter L ^a   White, Anne ^a   Gibson, J Martin ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Cardiovascular risk; Estrogen; Insulin like growth factor; Progestin

Indexed keywords

CONJUGATED ESTROGEN; DESOGESTREL; GESTAGEN; MEDROXYPROGESTERONE ACETATE; NORETHISTERONE; SOMATOMEDIN;

ADULT; ARTICLE; BONE DENSITY; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HORMONE RELEASE; HORMONE SUBSTITUTION; HUMAN; PERIPHERAL CIRCULATION; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RECEPTOR AFFINITY;

EID: 0033825429     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1067/mob.2000.106994     Document Type: Article

References (25)

1. Randomised trial of estrogen plus progestin for secondary prevention of heart disease in postmenopausal women
2. Uncoupling of bone formation and resorption by combined oestrogen and progestogen therapy in postmenopausal osteoporosis
3. Reduced insulin-like growth factor binding protein-1 (IGFBP-1) levels correlate with increased cardiovascular risk in non-insulin dependent diabetes mellitus (NIDDM)
4. Insulin-like growth factor system components and the coupling of bone formation to resorption
5. Acute and chronic oestrogen effects upon serum somatomedin activity, growth hormone and prolactin in man
6. Both oral and transdermal estrogen increase growth hormone release in postmenopausal women - A clinical research center study
7. Effects of oral and transdermal oestrogen replacement therapy on plasma levels of insulin-like growth factors and IGF binding proteins 1 and 3: A cross-over study
8. Insulin-like growth factors and their binding proteins: Biological actions
9. Effects of oral versus transdermal estrogen on the growth hormone/insulin-like growth factor axis in younger and older postmenopausal women: A clinical research centre study
10. Selectivity in progesterone and androgen receptor binding of progestogens used in oral contraceptives
11. Urinary IGF and IGF binding protein-3 in children with disordered growth
12. Radioimmunoassays for IGFs and IGFBPs
13. Measurement of insulin-like growth factor-II in human plasma using a specific monoclonal antibody-based two-site immunoradiometric assay
14. The phosphorylation pattern of insulin-like growth factor binding protein-1 in normal plasma is different from that in amniotic fluid and changes during pregnancy
15. Analysis of serum IGFBPs using Western blotting: Use of the method for titration of the binding proteins and competitive binding studies
16. Serum sex-hormone binding globulin is related to hepatic and peripheral insulin sensitivity but not to beta cell function in men and women with type 2 diabetes mellitus
17. Insulin-like growth factor binding protein-1 response to insulin during suppression of endogenous insulin secretion
18. Hormonal regulation of circulating IGFBP-1 phosphorylation status
19. Phasic serum lipid excursions occur during cyclical oral conjugated oestrogens but not during transdermal oestradiol sequentially combined with oral medroxyprogesterone acetate
20. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease
21. Prospective trial of oestrogen and calcium in postmenopausal women
22. Preliminary in situ identification of estrogen target cells in bone
23. Regulation and biological effect of endogenous insulin-like growth factor binding protein-5 in human osteoblastic cells
24. Monitoring of growth hormone replacement in adults, based on measurement of serum markers
25. Plasma insulin-like growth factor-I/somatomedin-C in acromegaly: Correlation with the degree of growth hormone hypersecretion